



The examiner requested an election of species with regards to claim 12, compounds that used in combination with Mst1 inhibitors in the method of the invention. The applicant's representative responded by stating that such a requirement is not appropriate since all the compounds in claim 12 are known to be useful in treating cardiac disease and are not germane with respect to the modality of the invention. In response the examiner agreed and removed the requirement.